Corporate R&D Tax Break Costs Billions in Federal Revenue

What it does

This bill restores the ability of businesses to immediately deduct research and development expenses as business costs rather than being forced to spread them over five years. It also allows companies to choose between immediate deduction or amortization, and coordinates the R&D tax credit with these deduction rules. The primary beneficiaries are corporations and businesses conducting research, who gain faster tax deductions and more flexibility in timing their tax benefits.

Why we flagged it

The bill's core mechanism is a tax-code amendment that accelerates the timing of R&D expense deductions for businesses, shifting from mandatory 5-year amortization to immediate deduction. This is a direct tax benefit to corporations, not a public-interest measure.

What the text implies

• The effective date (December 31, 2021) is retroactive, meaning the bill would apply to tax years already filed or in progress, potentially triggering amended returns and refunds for corporations with prior R&D spending.
• The bill permits taxpayers to elect between immediate deduction and 60-month amortization, giving corporations timing flexibility to optimize tax liability across years—a benefit unavailable to wage-earning individuals.
• Coordination with the R&D tax credit (§41) allows corporations to claim both the credit AND the deduction (with a reduced-credit election), potentially doubling the tax benefit for the same R&D spending.
• No requirement that tax savings be reinvested in R&D, worker compensation, or public benefit; corporations may use the deduction to reduce taxes while cutting R&D spending or wages.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill provides accelerated tax deductions to corporations and businesses conducting R&D, reducing federal tax revenue without offsetting public benefit or direct consumer protection. While R&D investment may eventually produce innovation, the immediate tax cost is borne by the general public through foregone revenue, and the bill contains no requirement that tax savings be reinvested in R&D, worker wages, or public benefit.

Who stands to gain

• technology companies
• pharmaceutical companies
• manufacturing firms with R&D operations
• biotech companies
• aerospace and defense contractors
• large corporations generally

Named in the bill

Internal Revenue Code of 1986, Section 174, Section 41 (R&D tax credit), Section 280C, Section 167 (depreciation), Section 611 (depletion), House Committee on Ways and Means

Where it stands

81 cosponsors: 41 Democrats, 39 Republicans, 1 Independents.

• Mar 10, 2025 — Introduced · Congress.gov: “Introduced in House”
• Mar 10, 2025 — Referred to House Committee on Ways and Means · Congress.gov: “Referred to the House Committee on Ways and Means”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

33 lobbying clients named this bill on 42 disclosure filings across 3 quarters, Dec 2025 to Jun 2026. Those filings disclosed $33,530,784 in lobbying spend. A filing names 9 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 98% of bills with at least one filing.

Ron Estes, the sponsor, reported $1,180,334 in PAC receipts in the 2026 cycle. $63,000 of that came from 11 PACs tied to these lobbying clients.

• Chamber of Commerce of the U.S.A. — $17,960,000 on 1 filing
• Dell Technologies Inc — $2,970,000 on 2 filings
• Boeing Company — $2,770,000 on 1 filing
• Abbvie Inc. — $2,490,000 on 2 filings
• Astrazeneca Pharmaceuticals Lp — $2,350,000 on 2 filings

Lobbying Disclosure Act filings through Jul 24, 2026. A filing shows who paid to lobby on a bill it names, not what changed.